Institutional Repository in Medical Sciences
(IRMS – Nicolae Testemițanu SUMPh)

Combined otologic drugs on pharmaceutical market of Moldova

Show simple item record

dc.contributor.author Luca, Angela
dc.contributor.author Staver, Olga
dc.date.accessioned 2021-11-23T10:36:31Z
dc.date.available 2021-11-23T10:36:31Z
dc.date.issued 2014
dc.identifier.citation LUCA, Angela, STAVER, Olga. Combined otologic drugs on pharmaceutical market of Moldova. In: MedEspera: the 5th Internat. Medical Congress for Students and Young Doctors: abstract book. Chișinău: S. n., 2014, pp. 239-240. en_US
dc.identifier.uri http://repository.usmf.md/handle/20.500.12710/18631
dc.description Department of Pharmaceutical and Toxicological Chemistry, State University of Medicine and Pharmacy "Nicolae Testemiţanu", Republic of Moldova en_US
dc.description.abstract Introduction: About one-tenth of medicinal products present on the pharmaceutical market are fixed-dose combinations. Fixed-dose combination products are becoming a popular treatment option because of increased patient’s compliance and convenience, improved clinical effectiveness, reduced cost for the patient and reduced side effects. Due to this range of advantages, combined drugs can be used in otorhinolaryngology practice, especially in the pharmacotherapy of ear diseases, because of the severe consequences otitis media produces (such as deafness due to keloid scars of the tympanic membrane). Materials and methods: For research, State Nomenclature of medicines from Republic of Moldova was used (26.03.2014); patient information leaflets; quality standards of analytical documents and therapeutic protocols in otorhinolaryngology (section "ear diseases"). Results: There are 642 combined drugs including: 531 combined drugs, 75 phytotherapeutic combined drugs and 36 biological combined drugs registered in State Nomenclature of drugs from Republic of Moldova. From these, approved drugs in otorhinolaryngology are 87 combined drugs, 20 phytotherapeutic combined drugs and 1 biological combined drug, which represents 13,55%, 3,11% and 0,15% from the total number of registered fixed-dose combination products, respectively, 16,38%, 26,67% and 2,77% from the number of registered specific combined products. There are 5 registered otological drugs which represents 0,78% from the total number of registered fixed-dose combination products and respectively, 0,94% from the number of registered specific combined products. From these: 40% represents anti-infectives, 20% represents analgesics and anesthetics and 40% represents corticosteroids and anti-infectives in combination. So, there is no specific anti-adhesive drug combination for the treatment of eardrum keloids. Conclusions: In conclusion it is important to develop a new anti-adhesive composition for the treatment of keloids of the tympanic membrane, containing raw vegetable materials. en_US
dc.language.iso en en_US
dc.publisher Ministry of Health of the Republic of Moldova, State Medical and Pharmaceutical University Nicolae Testemitanu, Medical Students and Residents Association en_US
dc.relation.ispartof MedEspera: The 5th International Medical Congress for Students and Young Doctors, May 14-17, 2014, Chisinau, Republic of Moldova en_US
dc.subject fixed-dose combinations en_US
dc.subject combined drugs en_US
dc.subject anti-adhesive substances en_US
dc.subject keloids en_US
dc.title Combined otologic drugs on pharmaceutical market of Moldova en_US
dc.type Other en_US


Files in this item

This item appears in the following Collection(s)

  • MedEspera 2014
    The 5th International Medical Congress for Students and Young Doctors, May 14-17, 2014

Show simple item record

Search DSpace


Advanced Search

Browse

My Account

Statistics